Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-29
2010-11-09
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07829577
ABSTRACT:
The present invention relates to SNS-595 and methods of treating cancer using the same.
REFERENCES:
patent: 5078996 (1992-01-01), Conlon, III et al.
patent: 5817669 (1998-10-01), Tomita et al.
patent: 6723734 (2004-04-01), Kim et al.
patent: 2003/0216316 (2003-11-01), Haran-Ghera et al.
patent: 2008/0063642 (2008-03-01), Adelman et al.
patent: 09-221424 (1997-08-01), None
patent: 11-349565 (1999-12-01), None
patent: WO 01/74395 (2001-10-01), None
patent: WO2005/089756 (2005-09-01), None
patent: WO 2007/028171 (2007-03-01), None
patent: WO 2007/146335 (2007-12-01), None
patent: WO 2008/016678 (2008-02-01), None
patent: WO 2009/054935 (2009-04-01), None
patent: WO 2009/075841 (2009-06-01), None
Ledwidge et al. International Journal of Pharmaceutics, 1998, vol. 174, pp. 187-200.
Allen, Database MEDLINE Accession No. 32345081, “Complications of Chemotherapy in Patients with Brain and Spinal Cord Tumors.” Ped. Neurosurg., vol. 17, No. 4, pp. 218-224, 1991-1992.
Chiba, et al., “Practical Synthesis of AG-7352, Optically Active New Antitumor Agent.” Abstract, 218thACS National Meeting, Aug. 22-26, 1999.
Evanchik, et al., “Non-Clinical Admet, PK, and Biological Activity of SNS-595, a Novel Cell Cycle Inhibitory Antineoplastic Agent.” Drug metabolism reviews, Marcel Dekker,New York, NY, US, vol. 36, No. SUPPLI, Aug. 2004 (2004-2008), p. 103.
Glaspy, et al., Database Cancerlit Accession No. 2002-047630, “A Dose-Finding and Safety Study of Novel Erythropoiesis Stimulating Protein (NESP) for the Treatment of Anaemia in Patients Receiving Multicicle Chemotherapy.” Br. J. Cancer, vol. 84 (Suppl. 1), pp. 17-23, Apr. 2001.
Herman, et al., Database MEDLINE Accession No. 78104303, “Nabilone: A Potent Antimetic Cannabinol with Minimal Euphoria.” Biomedicine, vol. 27, No. 9-10, pp. 331-334, Dec. 1977.
Kashimoto, et al., “Antitumor Activity of a Novel Quinolone Analog AG-7352 in Human Xenograft Models of Leukemia or Drug-Resistant Tumors and in an Experimental Metastatic Tumor Model.” Proceedings of the Annual Meeting of the American Association for Cancer Research. New York, NY, vol. 42, Mar. 2001. p. 102-Abstract 553.
Lawrence, et al., “SNS-595, a Novel S-Phase Active Cytotoxic, Demonstrates Pharmacologic Properties Appropriate for the Treatment of Advanced Hematologic Malignancies.” Blood, vol. 106, No. 11, Part 2, Nov. 2005, p. 2378.
Nakano, et al., “Antitumor Activity of a Novel Quinolone DNA Topoisomerase II Inhibitor AG-7352.” Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 40, Mar. 1999, p. 115-Abstract 767.
Ryffel, Database CANCERLIT Accession No. 97254190, “Safey of Human Recombinant Proteins.” Boimed. Envion. Sci. Vo. 10, No. 1, pp. 65-72, Mar. 1997.
Sato, et al., “In Vivo Antitumor Activity of a Novel Quinolone Analogue AG-7352 Against a Borad-Spectrum of Cancers and Drug-Resistant Human Cancers.” Abstract, 11thNCI-EOARTC-AACR symposium on new drugs in cancer therapy, Nov. 7-10, 2000.
Therasse, et al. “New Guidelines to Evaluate the Response to Treatment in Solid Tumors.” Journal of the National Cancer Institute, vol. 92, No. 3, Feb. 2, 2000.
Tolcher, et al., “Phase 1 and Pharmacokinetic Study of NSC 655649, a Reveccamycin Analog with Topoisomerase Inhibitory Properties.” Journal of Clinical Oncology, vol. 19, No. 11, Jun. 1, 2001.
Tomtia, et al., Database CAPLUS Acession No. 1999:92763, “Synthesis and Antitumor activity of Novel 7-Substituted 1,4-dihydro-4-oxo-1-2(2-thiazolyl)-1, 8-naphthyridine-3-carobxylic Acids”, BK Abstracts, 217thACS Nat Mtg., Mar. 21-25, 1999.
Tomitia, K. Synthesis and Structure-Activity Relationships of Novel 7-Substituted 1-4-Dihydro-4-oxo-1-(2-thiazolyl)-1, 8-naphthyridine-3-carboxylic Acids as Antitumor Agents. Part 1, J. Med. Chem. 2002, vol. 45, pp. 5564-5575, 2002.
Tsuzuki, et al., “Efficient Stereospecific Synthesis of (S,S)-3-Methoxy-4-Methylaminopyrrodlidine.” Tetrahedron: Asymmetry 12 (2001): 1793-1799.
Tsuzuki, et al., “Practical Synthesis of (3S,4S)-3-Methoxy-4-Methylaminopyrrolidine.” Tetrahedron: Asymmetry 12(2001) 2989-2997.
Tsuzuki, et al., “Process Research of a Novel Quinolone Antitumor Agent, AG-7352.” English Abstract, The Japanese Society for Process Chemstry, 2004 Summer Symposium.
Tsuzuki, et al., “Synthesis and Structure—Activity Relationships of 3-Substitued 1, 4-Dihydro-4-Oxo-1-(2-Thiazolyl)-1, 8-Naphthridines as Novel Antitumor Agents.” Bioorganic & Medicinal Chemistry Letters 14 (2004): 3189-3193.
Tsuzuki, et al., “Synthesis and Structure—Activity Relationships of Novel 7-Substituted 1.4-Dihydro-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acids as Antitumor Agents. Part 2.” J. Med. Chem. 2004, 47: 2097-2109.
Tsuzuki, et al., “Synthesis of Optically Active Amine at C-7 Position of New Antitumor Agent AG-7352.” Abstract, Molecular Chirality Conference, 1999.
Wright, et al., “SNS-595 Has Synergistic Activity in Vitro with DNA Damaging Agents and Antimetabolites.” Proceddings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 47, Apr. 2006, p. 504.
Ploemen et al.,Laboratory Animals, 2002, 36, 181-187.
Higaki Masaru
Nakao Satoshi
Anderson James D
Dainippon Sumitomo Pharma Co. ,Ltd.
Jones Day
Sunesis Pharmaceuticals, Inc.
LandOfFree
Pharmaceutical compositions of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244924